199 related articles for article (PubMed ID: 36923239)
1. Protective potential of the gallbladder in primary sclerosing cholangitis.
Cazzagon N; Gonzalez-Sanchez E; El-Mourabit H; Wendum D; Rainteau D; Humbert L; Corpechot C; Chazouillères O; Arrivé L; Housset C; Lemoinne S
JHEP Rep; 2023 Apr; 5(4):100649. PubMed ID: 36923239
[TBL] [Abstract][Full Text] [Related]
2. Suppression of bile acid synthesis as a tipping point in the disease course of primary sclerosing cholangitis.
Braadland PR; Schneider KM; Bergquist A; Molinaro A; Lövgren-Sandblom A; Henricsson M; Karlsen TH; Vesterhus M; Trautwein C; Hov JR; Marschall HU
JHEP Rep; 2022 Nov; 4(11):100561. PubMed ID: 36176935
[TBL] [Abstract][Full Text] [Related]
3. Downregulation of TGR5 (GPBAR1) in biliary epithelial cells contributes to the pathogenesis of sclerosing cholangitis.
Reich M; Spomer L; Klindt C; Fuchs K; Stindt J; Deutschmann K; Höhne J; Liaskou E; Hov JR; Karlsen TH; Beuers U; Verheij J; Ferreira-Gonzalez S; Hirschfield G; Forbes SJ; Schramm C; Esposito I; Nierhoff D; Fickert P; Fuchs CD; Trauner M; García-Beccaria M; Gabernet G; Nahnsen S; Mallm JP; Vogel M; Schoonjans K; Lautwein T; Köhrer K; Häussinger D; Luedde T; Heikenwalder M; Keitel V
J Hepatol; 2021 Sep; 75(3):634-646. PubMed ID: 33872692
[TBL] [Abstract][Full Text] [Related]
4. Defects in gallbladder emptying and bile Acid homeostasis in mice with cystic fibrosis transmembrane conductance regulator deficiencies.
Debray D; Rainteau D; Barbu V; Rouahi M; El Mourabit H; Lerondel S; Rey C; Humbert L; Wendum D; Cottart CH; Dawson P; Chignard N; Housset C
Gastroenterology; 2012 Jun; 142(7):1581-91.e6. PubMed ID: 22370478
[TBL] [Abstract][Full Text] [Related]
5. Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: A multicenter, randomized, double-blind, placebo-controlled phase II trial.
Hirschfield GM; Chazouillères O; Drenth JP; Thorburn D; Harrison SA; Landis CS; Mayo MJ; Muir AJ; Trotter JF; Leeming DJ; Karsdal MA; Jaros MJ; Ling L; Kim KH; Rossi SJ; Somaratne RM; DePaoli AM; Beuers U
J Hepatol; 2019 Mar; 70(3):483-493. PubMed ID: 30414864
[TBL] [Abstract][Full Text] [Related]
6. [A clinical and pathological analysis of 22 cases of primary sclerosing cholangitis].
Liu HH; Fu JL; Luo SQ; Sun YL; Dong JH; Guo TS; Wang FS
Zhonghua Gan Zang Bing Za Zhi; 2013 Feb; 21(2):125-8. PubMed ID: 23663885
[TBL] [Abstract][Full Text] [Related]
7. Loss of apical sodium bile acid transporter alters bile acid circulation and reduces biliary damage in cholangitis.
Meadows V; Marakovits C; Ekser B; Kundu D; Zhou T; Kyritsi K; Pham L; Chen L; Kennedy L; Ceci L; Wu N; Carpino G; Zhang W; Isidan A; Meyer A; Owen T; Gaudio E; Onori P; Alpini G; Francis H
Am J Physiol Gastrointest Liver Physiol; 2023 Jan; 324(1):G60-G77. PubMed ID: 36410025
[TBL] [Abstract][Full Text] [Related]
8. Survey uncovering variations in the management of primary sclerosing cholangitis across Europe.
Eliasson J; Lo B; Schramm C; Chazouilleres O; Folseraas T; Beuers U; Ytting H
JHEP Rep; 2022 Nov; 4(11):100553. PubMed ID: 36164416
[TBL] [Abstract][Full Text] [Related]
9. Potent suppression of hydrophobic bile acids by aldafermin, an FGF19 analogue, across metabolic and cholestatic liver diseases.
Sanyal AJ; Ling L; Beuers U; DePaoli AM; Lieu HD; Harrison SA; Hirschfield GM
JHEP Rep; 2021 Jun; 3(3):100255. PubMed ID: 33898959
[TBL] [Abstract][Full Text] [Related]
10. Cholangiocyte senescence in primary sclerosing cholangitis is associated with disease severity and prognosis.
Cazzagon N; Sarcognato S; Floreani A; Corrà G; De Martin S; Guzzardo V; Russo FP; Guido M
JHEP Rep; 2021 Jun; 3(3):100286. PubMed ID: 34041468
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of intestinal bile acid absorption improves cholestatic liver and bile duct injury in a mouse model of sclerosing cholangitis.
Baghdasaryan A; Fuchs CD; Österreicher CH; Lemberger UJ; Halilbasic E; Påhlman I; Graffner H; Krones E; Fickert P; Wahlström A; Ståhlman M; Paumgartner G; Marschall HU; Trauner M
J Hepatol; 2016 Mar; 64(3):674-81. PubMed ID: 26529078
[TBL] [Abstract][Full Text] [Related]
12. Prospective evaluation of ursodeoxycholic acid withdrawal in patients with primary sclerosing cholangitis.
Wunsch E; Trottier J; Milkiewicz M; Raszeja-Wyszomirska J; Hirschfield GM; Barbier O; Milkiewicz P
Hepatology; 2014 Sep; 60(3):931-40. PubMed ID: 24519384
[TBL] [Abstract][Full Text] [Related]
13. Sclerosing cholangitis with autoimmune pancreatitis versus primary sclerosing cholangitis: comparison on endoscopic retrograde cholangiography, MR cholangiography, CT, and MRI.
Kim JH; Byun JH; Kim SY; Lee SS; Kim HJ; Kim MH; Lee MG
Acta Radiol; 2013 Jul; 54(6):601-7. PubMed ID: 23528564
[TBL] [Abstract][Full Text] [Related]
14. Prevalence and risk factors for gallbladder neoplasia in patients with primary sclerosing cholangitis: evidence for a metaplasia-dysplasia-carcinoma sequence.
Lewis JT; Talwalkar JA; Rosen CB; Smyrk TC; Abraham SC
Am J Surg Pathol; 2007 Jun; 31(6):907-13. PubMed ID: 17527079
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of curcumin in primary sclerosing cholangitis: an open label pilot study.
Eaton JE; Nelson KM; Gossard AA; Carey EJ; Tabibian JH; Lindor KD; LaRusso NF
Scand J Gastroenterol; 2019 May; 54(5):633-639. PubMed ID: 31131678
[No Abstract] [Full Text] [Related]
16. Analysis of various ATP-binding cassette transporters revealed quantification of ABCB4 as a potential diagnostic tool in primary sclerosing cholangitis (PSC).
Thoeni C; Perciani CT; Nakib D; Camat D; McGilvray ID; MacParland SA; Fischer S
Histopathology; 2023 Oct; 83(4):559-568. PubMed ID: 37488782
[TBL] [Abstract][Full Text] [Related]
17. Methylation signatures in peripheral blood are associated with marked age acceleration and disease progression in patients with primary sclerosing cholangitis.
Trauner M; Gindin Y; Jiang Z; Chung C; Subramanian GM; Myers RP; Gulamhusein A; Kowdley KV; Levy C; Goodman Z; Manns MP; Muir AJ; Bowlus CL
JHEP Rep; 2020 Feb; 2(1):100060. PubMed ID: 32039401
[TBL] [Abstract][Full Text] [Related]
18. Prolonged fibroblast growth factor 19 response in patients with primary sclerosing cholangitis after an oral chenodeoxycholic acid challenge.
Zweers SJ; de Vries EM; Lenicek M; Tolenaars D; de Waart DR; Koelfat KV; Groen AK; Olde Damink SW; Beuers U; Ponsioen C; Jansen PL; Schaap FG
Hepatol Int; 2017 Jan; 11(1):132-140. PubMed ID: 27696157
[TBL] [Abstract][Full Text] [Related]
19. Safety and Sustained Efficacy of the Farnesoid X Receptor (FXR) Agonist Cilofexor Over a 96-Week Open-label Extension in Patients With PSC.
Trauner M; Bowlus CL; Gulamhusein A; Hameed B; Caldwell SH; Shiffman ML; Landis C; Muir AJ; Billin A; Xu J; Liu X; Lu X; Chung C; Myers RP; Kowdley KV
Clin Gastroenterol Hepatol; 2023 Jun; 21(6):1552-1560.e2. PubMed ID: 35934287
[TBL] [Abstract][Full Text] [Related]
20. Bile Acid Profiles in Primary Sclerosing Cholangitis and Their Ability to Predict Hepatic Decompensation.
Mousa OY; Juran BD; McCauley BM; Vesterhus MN; Folseraas T; Turgeon CT; Ali AH; Schlicht EM; Atkinson EJ; Hu C; Harnois D; Carey EJ; Gossard AA; Oglesbee D; Eaton JE; LaRusso NF; Gores GJ; Karlsen TH; Lazaridis KN
Hepatology; 2021 Jul; 74(1):281-295. PubMed ID: 33226645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
